SALT LAKE CITY--(BUSINESS WIRE)--Recursion, a tech-enabled biopharma company combining automation with artificial intelligence to discover novel treatments that expand our collective understanding of ...
And we're not just generating data to help discover targets or to help translate programs or to help with clinical trials. We're building a true end to end capability from target discovery all the way ...
Earnings call Recursion ended Q2 2025 with $533M in cash and reiterated its expected cash runway through Q4 2027. The company advanced multiple internal oncology and rare disease programs, hit its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback